Ivan Cheung

Bio:

Ivan Cheung is the Chief Executive Officer (CEO) and a member of the Board of Directors at NextPoint Therapeutics. He previously served as the U.S. CEO of Eisai, where he guided the significant growth of the North America business to over $1.5 billion in revenue. Under his leadership, lenvatinib was successively launched in a range of tumor types as monotherapy as well as in combination with a PD-1 inhibitor. Ivan also led the global R&D and first-ever full U.S. approval of a monoclonal antibody therapeutic to treat the underlying pathophysiology of early-stage Alzheimer’s disease with lecanemab. His stewardship led to the first wide reimbursement access from the Centers for Medicare & Medicaid Services for this class of medicines. In addition, Ivan held leadership roles in business development, corporate strategy, finance, and talent management at Eisai. Prior to Eisai, he advised pharmaceutical and biotech companies at Booz Allen Hamilton. Ivan received an MBA from Harvard Business School and a BSE from Duke University.